1FRE Stock Overview
A health care company, provides products and services for chronically ill patients.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 4/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Fresenius SE & Co. KGaA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €33.89 |
52 Week High | €34.80 |
52 Week Low | €23.93 |
Beta | 1.07 |
11 Month Change | 1.59% |
3 Month Change | 16.78% |
1 Year Change | 22.48% |
33 Year Change | -14.42% |
5 Year Change | -17.38% |
Change since IPO | -48.96% |
Recent News & Updates
Recent updates
Shareholder Returns
1FRE | IT Healthcare | IT Market | |
---|---|---|---|
7D | 1.7% | -1.7% | -3.1% |
1Y | 22.5% | -3.6% | 17.9% |
Return vs Industry: 1FRE exceeded the Italian Healthcare industry which returned -6.3% over the past year.
Return vs Market: 1FRE exceeded the Italian Market which returned 19.8% over the past year.
Price Volatility
1FRE volatility | |
---|---|
1FRE Average Weekly Movement | 2.9% |
Healthcare Industry Average Movement | 3.8% |
Market Average Movement | 4.1% |
10% most volatile stocks in IT Market | 6.7% |
10% least volatile stocks in IT Market | 2.5% |
Stable Share Price: 1FRE has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: 1FRE's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1912 | 175,771 | Michael Sen | www.fresenius.com |
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Fresenius SE & Co. KGaA Fundamentals Summary
1FRE fundamental statistics | |
---|---|
Market cap | €19.13b |
Earnings (TTM) | €721.00m |
Revenue (TTM) | €22.63b |
26.5x
P/E Ratio0.8x
P/S RatioIs 1FRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1FRE income statement (TTM) | |
---|---|
Revenue | €22.63b |
Cost of Revenue | €17.41b |
Gross Profit | €5.23b |
Other Expenses | €4.51b |
Earnings | €721.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 06, 2024
Earnings per share (EPS) | 1.28 |
Gross Margin | 23.09% |
Net Profit Margin | 3.19% |
Debt/Equity Ratio | 61.2% |
How did 1FRE perform over the long term?
See historical performance and comparison